07:08 AM EDT, 04/02/2025 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) said Wednesday that the latest results from a phase 2 trial of EDG-7500 showed "rapid and clinically meaningful reductions" in left ventricular outflow tract gradients in participants with obstructive hypertrophic cardiomyopathy.

A four-week treatment with EDG-7500 also showed "substantial improvements" in measures of feel and function, as well as reductions in key cardiac biomarkers and positive trends in measures of diastolic function, the company said.

Edgewise said the initial data read-out from the study's part D is expected in H2 2025, while the phase 3 study is planned to begin in H1 2026.

Hypertrophic cardiomyopathy is a form of genetic heart disease.